ANN ARBOR, Mich., Sept. 23 /PRNewswire-USNewswire/ -- Compendia Bioscience, Inc. today announced the release of Oncomine Research Edition version 4.2, a significant product upgrade for the academic and non-profit communities. Since its inception, Compendia has been fully committed to supporting academic and non-profit cancer research efforts worldwide. This new version of Oncomine features a completely redesigned user-interface, improved search and filter capabilities, and several other new features designed to make gene discovery and validation simpler and more efficient.
Cancer researchers have made Oncomine the industry standard with over 12,000 academic users. These researchers use Oncomine to discover new genes, evaluate pathways and better understand specific cancer types resulting in the publication of more than 200 peer reviewed journal articles. Oncomine has led to several major cancer research discoveries such as the recent publication of AGTR1 overexpression and sensitivity to losartan in breast cancer (Proc Natl Acad Sci U S A. 2009 Jun 1).
"We are really pleased to release this exciting new version of Oncomine to the academic research community," said Compendia's Co-Founder and CEO Dan Rhodes, Ph.D. "We are confident that Oncomine 4 will continue to accelerate cancer research and lead to important new discoveries."
New Features and Capabilities in Oncomine 4 Research Edition
- Unified interface, optimizing workflows with rapid navigation and visualization of results through three interactive panes
- Smart search and browse, giving users the ability to search multiple terms within a single instance
- The Compendia Ontology, standardizing a set of rules used to characterize Oncomine data, which drives consistent downstream analyses
- Standardized analyses, comparing gene expression profiles between norma
Page: 1 2 Related biology technology :1
|SOURCE Compendia Bioscience, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes2
. Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition3
. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience4
. On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability5
. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 266
. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.7
. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook8
. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry9
. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB10
. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update11
. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER